Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
167 hedge funds and large institutions have $287M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 30 closing their positions.
33% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 30
32% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $1.12M
21% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 47
1% more funds holding
Funds holding: 165 → 167 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $340M → $287M (-$52.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$41.4M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$10.9M |
| 3 |
Millennium Management
New York
|
+$6.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.55M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$6.78M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.41M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$5.02M |
| 4 |
TA
Teachers Advisors
New York
|
-$4.86M |
| 5 |
Renaissance Technologies
New York
|
-$4.04M |
SCMP Hedge Fund Activity: Q1 2017 in Review
167 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q1 2017, worth a combined $287M — down 16% from $340M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SCMP positions and 30 closed out — a net gain of 10 holders — while 57 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $41.4M. The largest seller was UBS O'Connor, exiting entirely with an estimated $6.78M sold.
- 167 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q1 2017, up from 165 in Q4 2016.
- Funds reported $287M of Sucampo Pharmaceuticals, Inc. stock for Q1 2017, down 16% quarter-over-quarter.
- 40 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q1 2017 and 30 closed out, a net change of +10 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $41.4M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q1 2017 was UBS O'Connor, an estimated $6.78M sold.
Based on aggregated 13F filings for Q1 2017.